THERAtRAME develops first-in-class small molecules that target tRNA epitranscriptomics to create new therapeutic options for patients with untreatable cancers. By leveraging advanced screening methods and pre-clinical validation systems, the platform identifies and positions novel drug candidates to address the limitations of existing cancer treatments.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail due to the cancer's ability to adapt through reprogramming protein expression. Existing therapies do not adequately address the role of tRNA epitranscriptomics in this process, leaving a significant unmet need for novel therapeutic approaches.
Solution
THERAtRAME is developing first-in-class small molecule inhibitors targeting tRNA epitranscriptomics to create new therapeutic options for patients with cancers that are currently untreatable or resistant to existing therapies. The company's platform integrates advanced screening methods, mathematical predictive models, and pre-clinical validation systems to discover and position novel drug candidates. By focusing on tRNA modifications that promote cellular adaptation and drive cancer progression, THERAtRAME aims to provide innovative cancer therapies that overcome the limitations of current treatments. The platform leverages cutting-edge science and artificial intelligence to identify and validate new drug targets within the tRNA epitranscriptome.
Target Audience
The primary target audience includes cancer patients with untreatable or resistant cancers, as well as oncologists and researchers seeking innovative therapeutic solutions.
Features
- Identification of novel tRNA epitranscriptomics targets for cancer therapy
- Discovery of potent and specific small molecule inhibitors of the tRNA epitranscriptome
- Pre-clinical validation systems for efficient testing of new drugs
- Analysis methods for positioning tRNA epitranscriptomics-targeting drugs in oncological diseases
- Integration of mathematical predictive models and artificial intelligence for treatment discovery